Patents Assigned to CHELATOR
  • Publication number: 20100086648
    Abstract: The present invention relates to the transformation of food-grade sugars containing D-fructose, in caramels enriched in oligosaccharides with prebiotic activity by using solid acid catalysts, such as zeolites, clays or ion-exchange resins in its acid form, under heterogeneous conditions, or by using soluble acid polymer catalysts of high molecular weight, under homogeneous conditions, with the possibility of recycling the catalyst, being compatible with discontinuous or continuous production processes. The resulting caramel exhibits prebiotic properties, favoring the development of a beneficial intestinal flora and a repairing effect in the damaged colon.
    Type: Application
    Filed: March 7, 2008
    Publication date: April 8, 2010
    Applicants: UNIVERSIDAD DE SEVILLA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, UNIVERSIDAD DE GRANADA, CHELATOR S.A.
    Inventors: Miguel Enrique Rubio Castillo, Marta Gomez Garcia, Carmen Ortiz Mellet, Manuel Jose Garcia Fernandez, Antonio Zarzuelo Zurita, Juan Julio Galvez Peralta, Raphael Duval
  • Publication number: 20090095681
    Abstract: The invention relates to novel p-tert butylcalix[6]arenes of formulae (IA) and (IB) with carboxylic or hydroxyamino triacidic functions in positions 2, 4 and 6, and other functions in positions 1, 3 and 5, supported liquid membranes and support materials comprising the above and the uses thereof.
    Type: Application
    Filed: May 16, 2006
    Publication date: April 16, 2009
    Applicants: CHELATOR, INSTITUT DE RADIOPROTECTION ET DE SURETE NUCLEAIR (I.R.S.N.)
    Inventors: Raphael Duval, Catherine Cossonet, Celine Bouvier-Capely
  • Patent number: 6881732
    Abstract: Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.
    Type: Grant
    Filed: June 13, 2002
    Date of Patent: April 19, 2005
    Assignees: Chelator LLC, Concat, Ltd.
    Inventor: Harry S. Winchell
  • Publication number: 20040006055
    Abstract: Compounds that demonstrate chelation affinity and selectivity for first transition series elements are administered to patients suffering from such conditions as ischemia, prolonged seizures and trauma to provide neuroprotection, cardioprotection, or both. These compounds when administered form complexes with chelatable iron and copper cations and thereby mitigate the ability of these cations to catalyze Haber-Weiss reactions that form toxic hydroxy free radicals that cause tissue injury. These compounds also form complexes with chelatable zinc cations thereby inhibiting the cytotoxicity associated with excess chelatable zinc.
    Type: Application
    Filed: June 13, 2002
    Publication date: January 8, 2004
    Applicants: CONCAT, LTD. a California Limited Partnership, CHELATOR LLC., a Delaware corporation
    Inventor: Harry S. Winchell
  • Patent number: 6583182
    Abstract: This invention involves synthesis and use of a class of compounds with chelation affinity and selectivity for first transition series elements. Administration of the free or conjugated compound, or physiological salts of the free or conjugated compound, results in decrease in the in vivo bioavailability of first transition series elements and/or removal from the body of first transition series elements and elements with similar chemical properties. These characteristics make such compounds useful in the management of diseases associated with a bodily excess of first transition series elements and elements with similar chemical properties. This invention demonstrates that such compounds inhibit mammalian, bacterial, and fungal cell replication and are therefore useful in the treatment of neoplasia, infection, inflammation, immune reponse, and in termination of pregnancy.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: June 24, 2003
    Assignee: Chelator LLC
    Inventors: Harry S Winchell, Joseph Y Klein, Elliot D Simhon, Rosa L Cyjon, Ofer Klein, Haim Zaklad
  • Patent number: 6576760
    Abstract: Polyamines containing at least two nitrogen atoms monosubstituted with pendant arms capable of coordinating metal cations, or with precursors of such pendant arms, all nitrogen atoms of the polyamines except two being fully substituted and the remaining two bearing one H atom each, are cyclized by reaction with a bridging agent that contains two sites that each bear a reactive group capable of undergoing a nucleophilic attack by one of the two N-H groups on the polyamine. Unlike the prior art, cyclization occurs in preference over polymerization of the polyamine, even in reaction mixtures in which the polyamine is at high concentration. A process is also disclosed whereby linear polyamines in which the terminal amine groups are primary amines are substituted with methylenephosphonate ester groups, with one such substituent on each nitrogen atom of the polyamine.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: June 10, 2003
    Assignee: Chelator LLC
    Inventors: Harry S. Winchell, Rosa L. Cyjon, Joseph Y. Klein, Elliot D. Simhon, Ofer Klein, Haim Zaklad